KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Quest Diagnostics (DGX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Quest Diagnostics (DGX) over the last 17 years, with Q3 2025 value amounting to 13.71%.

  • Quest Diagnostics' EBITDA Margin rose 4400.0% to 13.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.11%, marking a year-over-year increase of 9900.0%. This contributed to the annual value of 13.63% for FY2024, which is 100.0% down from last year.
  • Quest Diagnostics' EBITDA Margin amounted to 13.71% in Q3 2025, which was up 4400.0% from 15.86% recorded in Q2 2025.
  • In the past 5 years, Quest Diagnostics' EBITDA Margin registered a high of 24.26% during Q1 2021, and its lowest value of 5.79% during Q4 2022.
  • Its 5-year average for EBITDA Margin is 15.63%, with a median of 14.88% in 2023.
  • In the last 5 years, Quest Diagnostics' EBITDA Margin surged by 146600bps in 2021 and then tumbled by -137500bps in 2022.
  • Over the past 5 years, Quest Diagnostics' EBITDA Margin (Quarter) stood at 19.53% in 2021, then tumbled by -70bps to 5.79% in 2022, then soared by 102bps to 11.67% in 2023, then grew by 18bps to 13.77% in 2024, then decreased by 0bps to 13.71% in 2025.
  • Its EBITDA Margin stands at 13.71% for Q3 2025, versus 15.86% for Q2 2025 and 13.05% for Q1 2025.